Diabetische Ketoazidose bei einer Patientin mit HNF4A-MODY

Zusammenfassung

Eine 27-jährige Patientin mit HNF4A-Maturity Onset Diabetes of the Young (MODY) wurde zur Behandlung einer schweren diabetischen Ketoazidose (DKA) und eines fortgeschrittenen diabetischen Fußsyndroms infolge einer fehlenden Therapieadhärenz stationär aufgenommen. Die DKA konnte im Rahmen eines kurzzeitigen Aufenthaltes auf der Intensivstation beherrscht werden und der Glukosestoffwechsel nach Initiierung einer intensivierten konventionellen Insulintherapie und einer umfassenden und individuellen Diabetesschulung langfristig optimiert werden. Dank intensiver Bemühungen des interdisziplinären Behandlungsteams konnte eine Fußamputation vermieden werden und die Wunden zur Abheilung gebracht werden. Angesichts unserer Fallbeschreibung und früherer Fallbeschreibungen von Patienten mit anderen MODY-Formen, bei denen es bei Erstdiagnose oder im Krankheitsverlauf zu einer DKA kam, sollte an dem in den aktuellen Kriterien zur Diagnose eines MODY geforderten Fehlen einer DKA nicht länger festgehalten und diese Kriterien entsprechend modifiziert werden. Zudem sollten die betroffenen Patienten angesichts der unverändert hohen Mortalität einer DKA umfassend geschult werden.

Abstract

A 27-year-old female patient with HNF4A-Maturity Onset Diabetes of the Young (MODY) was admitted to hospital for treatment of severe diabetic ketoacidosis (DKA) and advanced diabetic foot syndrome due to a lack of adherence to therapy. The DKA was controlled during a short stay in the intensive care unit and the glucose metabolism was optimised in the long term after initiating an intensified conventional insulin therapy and a comprehensive and individual diabetes training. Thanks to intensive efforts of the interdisciplinary treatment team, foot amputation was avoided and the wounds were brought to healing. In view of our case report and earlier case reports of patients with other forms of MODY who developed DKA at initial diagnosis or in the course of the disease, the absence of DKA required in the current criteria for the diagnosis of MODY should no longer be adhered to and these criteria should be modified accordingly. In addition, the affected patients should be comprehensively educated in view of the unchanged high mortality of DKA.

Schlüsselwörter

Maturity Onset Diabetes of the Young - Diabetische Ketoazidose - Diagnostische Kriterien

Keywords

Maturity Onset Diabetes of the Young - Diabetic ketoacidosis - Diagnostic criteria

Publication History

Received: 27 September 2023

Accepted after revision: 28 November 2023

Article published online:
27 February 2024

• Literatur

• 1 Emmelheinz M, Knebel B, Müssig K. Diagnose und Behandlung des Maturity-Onset Diabetes of the Young (MODY). Diabetol Stoffwechs 2021; 16: 378-391
• 2 Gardner DS, Tai ES. Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes 2012; 5: 101-108
• 3 Hattersley A, Bruining J, Shield J. et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009; 10 (Suppl. 12) 33-42
• 4 Stride A, Vaxillaire M, Tuomi T. et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002; 45: 427-435
• 5 Isomaa B, Henricsson M, Lehto M. et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998; 41: 467-473
• 6 Steele AM, Shields BM, Shepherd M. et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010; 27: 157-161
• 7 Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975; 24: 44-53
• 8 Ge S, Yang M, Gong W. et al. Case Report: A case of HNF1B mutation patient with first presentation of diabetic ketosis. Front Endocrinol (Lausanne) 2022; 13: 917819
• 9 Hayakawa-Iwamoto A, Aotani D, Shimizu Y. et al. Maturity-onset diabetes of the young type 5, presenting as diabetic ketoacidosis with alkalemia: A report of a case. J Diabetes Investig 2022; 13: 923-926
• 10 Horikawa Y, Enya M, Mabe H. et al. NEUROD1-deficient diabetes (MODY6): Identification of the first cases in Japanese and the clinical features. Pediatr Diabetes 2018; 19: 236-242
• 11 Kondoh T, Nakajima Y, Yokoi K. et al. Identification of a Novel Mutation in Carboxyl Ester Lipase Gene in a Patient with MODY-like Diabetes. Tohoku J Exp Med 2022; 256: 37-41
• 12 Molven A, Ringdal M, Nordbø AM. et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes 2008; 57: 1131-1135
• 13 Johnson SR, McGown I, Oppermann U. et al. A novel INS mutation in a family with maturity-onset diabetes of the young: Variable insulin secretion and putative mechanisms. Pediatr Diabetes 2018; 19: 905-909
• 14 Pruhova S, Dusatkova P, Neumann D. et al. Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: is it time to change the diagnostic criteria for MODY?. Diabetes Care 2013; 36: 2573-2574
• 15 Egan AM, Cunningham A, Jafar-Mohammadi B. et al. Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young. BMJ Case Rep 2015; 2015: bcr2014209163
• 16 Cheng Y, Zhong DP, Ren L. et al. Unusual manifestations of young woman with MODY5 based on 17q12 recurrent deletion syndrome. BMC Endocr Disord 2022; 22: 77
• 17 Kadota-Shinozaki A, Nakamura T. et al. Diabetic lipemia with maturity-onset diabetes of the young. Intern Med 1997; 36: 571-574
• 18 Phan F, Bourron O, Laroche S. et al. Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3. Diabetes Metab 2021; 47: 101248
• 19 Hohendorff J, Szopa M, Skupien J. et al. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. Endocrine 2017; 57: 272-279
• 20 Shand JAD, Morrow P, Braatvedt G. Mortality after discharge from hospital following an episode of diabetic ketoacidosis. Acta Diabetol 2022; 59: 1485-1492